
    
      A randomized, double-blind, placebo-controlled clinical trial in 24 patients with a diagnosis
      of prediabetes in accordance with the American Diabetes Association (ADA) without treatment.

      They will be assigned randomly two groups of 12 patients each to receive 10 mg of
      Dapagliflozin (Forxiga, Astra Zeneca) or placebo, one per day before breakfast during 12
      weeks.

      There will be calculated Area Under the Curve of glucose and insulin, total insulin secretion
      (Insulinogenic index), first-phase of insulin secretion (Stumvoll index) and insulin
      sensitivity (Matsuda index).

      This protocol it's already approved by the local ethics committee and written informed
      consent it's going to be obtained from all volunteers.

      Statistical analysis will be presented through measures of central tendency and dispersion,
      average and deviation standard for quantitative variables; frequencies and percentages for
      variable qualitative. Qualitative variables will be analyzed by X2, will be used for
      differences inter-group Mann-Whitney U Test and Wilcoxon Test for the within-groups
      differences. It will be considered statistical significance p â‰¤0.05.

      This protocol was approved by a local ethics committee and written informed consent will be
      obtained from all volunteers.
    
  